Avalanche Biotechnologies develops technologies and products for sustained delivery of therapeutic proteins to the eye to treat age-related macular degeneration (AMD) and other ophthalmologic disorders.
Meta Keywords
Avalanche, Avalanche Biotech, Avalanche Biotechnologies, Biotechnology, BioFactory, Wet AMD, AMD, Age-Related Macular Degeneration, AAV, Adeno-associated virus, Gene Therapy, Therapeutic products, Therapeutic protein, Ophthalmology, Ocular, Eye, Retina, Retinal disease, Retinal degeneration, Diabetic retinopathy, Diabetic macular edema, Glaucoma, Blindness, Vision research, Vitreoretinal disease, Drug delivery, Novel technologies, Protein pharmaceuticals, AVA-101, Thomas Chalberg, Steven Schwatrz, Steve Schwartz, Mark Blumenkranz, Mitchell Finer, biotech companies in san francisco, biotech startups in bay area, clinical trials, clinical testing, biologics, gene therapy